Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Brainstorm Cell Therapeutics (BCLI) stocks in Canada

Learn how to easily invest in Brainstorm Cell Therapeutics stocks.

Brainstorm Cell Therapeutics is a biotechnology business based in the US. Brainstorm Cell Therapeutics stocks (BCLI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.43 – a decrease of 5.16% over the previous week. Brainstorm Cell Therapeutics employs 40 staff and has a market cap (total outstanding stock value) of $112.5 million.

How to buy shares in Brainstorm Cell Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCLI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Brainstorm Cell Therapeutics stock price (NASDAQ:BCLI)

Use our graph to track the performance of BCLI stocks over time.

Brainstorm Cell Therapeutics shares at a glance

Information last updated 2022-01-24.
Latest market close$2.94
52-week range$2.75 - $8.14
50-day moving average $3.50
200-day moving average $3.45
Wall St. target price$11.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.85

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Brainstorm Cell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Brainstorm Cell Therapeutics price performance over time

Historical closes compared with the close of $2.94 from 2022-01-27

1 week (2022-01-17) N/A
1 month (2021-12-24) N/A
3 months (2021-10-28) 2.44%
6 months (2021-07-28) -17.65%
1 year (2021-01-28) -53.37%
2 years (2020-01-28) -29.33%
3 years (2019-01-28) 3.61
5 years (2017-01-27) 3.89%

Brainstorm Cell Therapeutics financials

Gross profit TTM $0
Return on assets TTM -55.44%
Return on equity TTM -118.19%
Profit margin 0%
Book value $0.69
Market capitalisation $112.5 million

TTM: trailing 12 months

Brainstorm Cell Therapeutics share dividends

We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.

Have Brainstorm Cell Therapeutics's shares ever split?

Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 15 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.

Brainstorm Cell Therapeutics share price volatility

Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $2.75 up to $8.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is -0.1029. This would suggest that Brainstorm Cell Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Brainstorm Cell Therapeutics has bucked the trend.

Brainstorm Cell Therapeutics overview

Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc.

Stocks similar to Brainstorm Cell Therapeutics

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site